Global Collaboration

Overview

We are leading the Canebosem Project to research and develop cannabinoid-based medicines for the prevention and management of diabetes. We believe that cannabinoids can play an important role as a cost-effective tool in personalized care plans for patients struggling with diabetes.


Our Partners

Project Goals
To improve diabetes care, the Canebosem Project:

• Engages in translational cannabinoid research with in-vivo patients to initiate innovation towards further understanding the therapeutic value of cannabinoids in, both, managing diabetes and preventing the onset of long-term complications like cancer, eye disease, and wound healing.
• Dedicates its resources to better understand the science of cannabinoids and its role in resolving the racial and ethnic health disparities seen in patients with diabetes.
• Generates evidence-based data on the effectiveness of cannabinoid therapy in various populations with type 2 diabetes, in order to optimize formulas for independent or combination therapies for personalized care plans.
  
  

Project Motivation

OneGuild and the Canebosem Project partners believe in the role that cannabinoid therapy plays in lipid signaling and metabolism, the safety of its pharmaceutical application, and its cost-effectiveness for underserved communities. We seek to advance research on relevant medical cannabinoids, and support the development of standardized, effective, and non-psychoactive medicine.

Can cannabinoid treatment play a role in helping patients manage diabetes and its complications? Cannabidiol (CBD), the second leading active compound in cannabis, is already being used in isolation without long-term adverse effect. In Canada, Spain, and the United Kingdom, CBD is approved for prescribed treatment of inflammation and cancer, with successful results. Chronic inflammation has long been known to be involved in the development of insulin resistance, diabetes, and many of its complications.

Can cannabinoids be used for patients with prediabetes to prevent onset of the disease altogether? Early clinical trials are substantiating the role of the body’s endocannabinoid system in the pathogenesis of diabetes. For example, patients receiving a RIO treatment (the antagonist to the CB1 cannabinoid receptor) showed greater weight loss and glycemic control when compared to placebo. The patients had previously been inadequately controlled by either metformin or sulfonylureas.